Richard Klasa

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Laurie H. Sehn, Brian Berry, Mukesh Chhanabhai et al. · Blood · 2006 · 1.5K citations

Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia

Laurie H. Sehn, Jane Donaldson, Mukesh Chhanabhai et al. · Journal of Clinical Oncology · 2005 · 982 citations · Full text

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

Marinus H. J. van Oers, Richard Klasa, Robert Marcus et al. · Blood · 2006 · 592 citations · Full text

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

Nathalie A. Johnson, Kerry J. Savage, Olga Ludkovski et al. · Blood · 2009 · 579 citations · Full text

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 569 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +9